🇺🇸 US

JAZZ revenue, net income and debt history (Jazz Pharmaceuticals plc)

Quick answer

Jazz Pharmaceuticals plc (JAZZ) reported revenue of $4.27B and net loss of $356.1M for the fiscal year ended 2025-12-31, up 4.9% from $4.07B the year before, per its 10-K filed with the SEC on 2026-02-24. Long-term debt stood at $5.36B.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$4.27B-$356.1M$5.36B
2024 (FY ending 2024-12-31)$4.07B$560.1M$6.11B
2023 (FY ending 2023-12-31)$3.83B$414.8M$5.71B
2022 (FY ending 2022-12-31)$3.66B-$224.1M$5.72B
2021 (FY ending 2021-12-31)$3.09B-$329.7M$6.05B
2020 (FY ending 2020-12-31)$2.36B$238.6M$2.09B
2019 (FY ending 2019-12-31)$2.16B$523.4M$1.61B
2018 (FY ending 2018-12-31)$1.89B$447.1M$1.60B
2017 (FY ending 2017-12-31)$1.62B$487.8M$1.58B
2016 (FY ending 2016-12-31)$1.49B$396.8M$2.03B

Related

Last updated 2026-10-16. Data only, not financial or tax advice.